title: Palbociclib for hormone receptor-positive breast cancer.
authors.forename: Emilia
authors.initials: E
authors.lastname: Harding
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008875:Middle Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D016001:Confidence Intervals; D018572:Disease-Free Survival; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077267:Fulvestrant; D009361:Neoplasm Invasiveness / Q000473:pathology; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects; D017698:Postmenopause; D017697:Premenopause; D016016:Proportional Hazards Models; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D004958:Estradiol; D000077267:Fulvestrant; D010879:Piperazines; D011725:Pyridines; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C500026:palbociclib